Thomas E. Mürdter

4.4k total citations
109 papers, 3.2k citations indexed

About

Thomas E. Mürdter is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Thomas E. Mürdter has authored 109 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Molecular Biology, 34 papers in Pharmacology and 31 papers in Oncology. Recurrent topics in Thomas E. Mürdter's work include Pharmacogenetics and Drug Metabolism (33 papers), Estrogen and related hormone effects (28 papers) and Inflammatory mediators and NSAID effects (13 papers). Thomas E. Mürdter is often cited by papers focused on Pharmacogenetics and Drug Metabolism (33 papers), Estrogen and related hormone effects (28 papers) and Inflammatory mediators and NSAID effects (13 papers). Thomas E. Mürdter collaborates with scholars based in Germany, United States and Australia. Thomas E. Mürdter's co-authors include Matthias Schwab, Michel Eichelbaum, Georg Heinkele, Ulrich M. Zanger, Péter Fritz, Hiltrud Brauch, Ute Hofmann, Reinhold Kerb, Godehard Friedel and Ulrich Klotz and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Environmental Science & Technology.

In The Last Decade

Thomas E. Mürdter

107 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas E. Mürdter Germany 31 943 926 845 436 402 109 3.2k
D. Kim Turgeon United States 32 1.1k 1.1× 1.4k 1.5× 895 1.1× 192 0.4× 679 1.7× 79 3.9k
Jan Snoeys Belgium 33 1.2k 1.3× 897 1.0× 906 1.1× 225 0.5× 529 1.3× 94 3.7k
Balram Chowbay Singapore 37 1.4k 1.5× 1.7k 1.9× 1.3k 1.6× 355 0.8× 248 0.6× 109 4.2k
David Jones United States 29 792 0.8× 819 0.9× 679 0.8× 142 0.3× 217 0.5× 58 2.4k
Junko Watanabe Japan 29 1.9k 2.0× 400 0.4× 612 0.7× 436 1.0× 244 0.6× 141 4.6k
Maciej Czerwiński United States 15 1.9k 2.0× 1.1k 1.2× 781 0.9× 230 0.5× 117 0.3× 22 4.1k
Harshad Devarbhavi India 24 935 1.0× 585 0.6× 1.4k 1.7× 114 0.3× 894 2.2× 84 5.5k
M. José Gómez‐Lechón Spain 38 1.2k 1.3× 991 1.1× 1.8k 2.2× 146 0.3× 671 1.7× 82 4.4k
Francisco J. López‐Hernández Spain 28 1.1k 1.2× 409 0.4× 380 0.4× 155 0.4× 268 0.7× 104 3.9k
Thomas Szekeres Austria 37 2.2k 2.3× 865 0.9× 232 0.3× 175 0.4× 376 0.9× 198 5.4k

Countries citing papers authored by Thomas E. Mürdter

Since Specialization
Citations

This map shows the geographic impact of Thomas E. Mürdter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Mürdter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Mürdter more than expected).

Fields of papers citing papers by Thomas E. Mürdter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Mürdter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Mürdter. The network helps show where Thomas E. Mürdter may publish in the future.

Co-authorship network of co-authors of Thomas E. Mürdter

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas E. Mürdter. A scholar is included among the top collaborators of Thomas E. Mürdter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas E. Mürdter. Thomas E. Mürdter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mürdter, Thomas E., Werner Schroth, Matthew P. Goetz, et al.. (2025). Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial. Clinical Cancer Research. 31(23). 4903–4911.
2.
Schroth, Werner, Thomas E. Mürdter, & Matthias Schwab. (2025). Unraveling the Impact of Drug Metabolism on Tamoxifen Response in Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 34(2). 221–223. 1 indexed citations
3.
Mürdter, Thomas E., Georg Heinkele, Matthias Schwab, et al.. (2023). Identification and synthesis of ( Z )‐3′‐hydroxy clomiphene as a new potential doping‐relevant metabolite of clomiphene. Rapid Communications in Mass Spectrometry. 37(17). e9599–e9599. 5 indexed citations
4.
5.
Janssen, Nicole, Thomas Sell, Svetlana Kalmykova, et al.. (2022). Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer. Molecular Cancer Therapeutics. 21(5). 799–809. 12 indexed citations
6.
Michelet, Robin, Madelé van Dyk, Thomas E. Mürdter, et al.. (2021). Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies. Pharmaceuticals. 14(2). 115–115. 3 indexed citations
7.
Koch, J., Nicole Janssen, Thomas E. Mürdter, et al.. (2021). A human ex vivo coculture model to investigate peritoneal metastasis and innovative treatment options. SHILAP Revista de lepidopterología. 6(3). 121–129. 8 indexed citations
8.
Michelet, Robin, Madelé van Dyk, Thomas E. Mürdter, et al.. (2021). Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups. Cancers. 13(10). 2432–2432. 2 indexed citations
9.
Schroth, Werner, Thomas E. Mürdter, Robin Michelet, et al.. (2020). Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. Clinical Pharmacology & Therapeutics. 108(3). 661–670. 21 indexed citations
10.
Mack, Alexandra, Kai Cao, Gavin Fullstone, et al.. (2020). Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids. Cell Death and Differentiation. 27(11). 3037–3052. 20 indexed citations
11.
Schroth, Werner, Thomas E. Mürdter, Reiner Hoppe, et al.. (2019). The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer. Clinical and Translational Science. 13(2). 284–292. 12 indexed citations
12.
Schwab, Matthias, Christoph Ulmer, Simon Heine, et al.. (2016). Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest. Cancer Research. 76(10). 2868–2875. 60 indexed citations
13.
14.
Schroth, Werner, Kathrin Klein, Hiltrud Brauch, et al.. (2013). The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7. Drug Metabolism and Disposition. 41(11). 1906–1913. 8 indexed citations
15.
Dong, Meng, Godehard Friedel, Andreas Grabner, et al.. (2012). Cancer Cells Cue the p53 Response of Cancer-Associated Fibroblasts to Cisplatin. Cancer Research. 72(22). 5824–5832. 24 indexed citations
16.
Nafee, Noha, Marc Schneider, Meng Dong, et al.. (2011). Treatment of lung cancer via telomerase inhibition: Self-assembled nanoplexes versus polymeric nanoparticles as vectors for 2′-O-Methyl-RNA. European Journal of Pharmaceutics and Biopharmaceutics. 80(3). 478–489. 29 indexed citations
17.
Kuip, Heiko van der, Thomas E. Mürdter, Maike Sonnenberg, et al.. (2006). Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer. 6(1). 86–86. 85 indexed citations
18.
Mürdter, Thomas E., Sebastian Taetz, Christiane Baldes, et al.. (2005). Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors. Laboratory Investigation. 85(12). 1565–1569. 25 indexed citations
19.
Coller, Janet K., Kathrin Klein, Renzo Wolbold, et al.. (2003). Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. British Journal of Clinical Pharmacology. 57(1). 105–111. 23 indexed citations
20.
Mürdter, Thomas E., Bernhard Sperker, Klaus Bosslet, Péter Fritz, & Heyo K. Kroemer. (1998). Simultaneous high-performance liquid chromatographic determination of a glucuronyl prodrug of doxorubicin, doxorubicin and its metabolites in human lung tissue. Journal of Chromatography B Biomedical Sciences and Applications. 709(2). 289–295. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Kim Turgeon Breakdown of academic impact, for papers by Jan Snoeys Breakdown of academic impact, for papers by Balram Chowbay Breakdown of academic impact, for papers by David Jones Breakdown of academic impact, for papers by Junko Watanabe Breakdown of academic impact, for papers by Maciej Czerwiński Breakdown of academic impact, for papers by Harshad Devarbhavi Breakdown of academic impact, for papers by M. José Gómez‐Lechón Breakdown of academic impact, for papers by Francisco J. López‐Hernández Breakdown of academic impact, for papers by Thomas Szekeres
Rankless by CCL
2026